Trop2 antibody-drug conjugate

Trophoblast cell-surface antigen 2 (Trop2) antibody-drug conjugates (ADCs) are a class of targeted oncology therapeutics designed to deliver potent cytotoxic payloads directly to cancer cells overexpressing the Trop2 glycoprotein. Trop2 is a transmembrane calcium signal transducer highly expressed in various epithelial tumors, including breast, lung, gastric, and urothelial cancers, while maintaining limited expression in normal tissues. These conjugates typically consist of a humanized anti-Trop2 monoclonal antibody linked to a cytotoxic agent—most commonly a topoisomerase I inhibitor like SN-38 or deruxtecan—via a stable or conditionally cleavable linker. Upon binding to the Trop2 receptor on the tumor cell surface, the ADC is internalized through receptor-mediated endocytosis, followed by lysosomal degradation or linker cleavage that releases the payload. The released toxin then induces DNA damage and apoptosis. This class includes the approved agent sacituzumab govitecan and several investigational agents such as datopotamab deruxtecan, SKB264, and ESG401.

Other names

Trop2-directed antibody-drug conjugateTrop-2-directed antibody-drug conjugateTrop 2-directed antibody-drug conjugateTrop-2 ADCTrop2 ADCTrop 2 ADCTrophoblast cell-surface antigen 2 antibody-drug conjugate